Rockwell Medical regains compliance with Nasdaq listing rules

Rockwell Medical, Inc. has regained compliance with the minimum bid price requirement mandated by The Nasdaq Stock Market LLC. The company received confirmation that its shares maintained a closing bid price of $1.00 or greater for the required period between July 1, 2026 and July 15, 2026. As a result, Nasdaq has formally closed the review of the company's listing status.

The compliance was achieved under Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid price standard for continued listing. Rockwell Medical is now in full compliance with all applicable continued listing requirements. The company's common stock continues to trade on the Nasdaq Capital Market under the symbol RMTI.

Compliance Details

The following table outlines the specific criteria met by Rockwell Medical to satisfy the exchange's requirements:

Requirement	Compliance Period	Minimum Bid Price	Outcome
Nasdaq Listing Rule 5550(a)(2)	July 1, 2026 to July 15, 2026	$1.00	Matter closed by Nasdaq

Rockwell Medical develops, manufactures, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The company focuses on delivering products and services to dialysis clinics and patients suffering from end-stage kidney disease.

Rockwell Medical, Inc. will release its financial and operational results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. The company develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The announcement will provide insights into its performance during the quarter.

The company will issue a press release at 6:00 a.m. ET, followed by a live webcast at 8:00 a.m. ET. The webcast will include a discussion of the second quarter 2026 financial and operational results, followed by a question-and-answer session.

Webcast Details

Detail	Information
Date	Thursday, August 13, 2026
Time	8:00 a.m. ET
Webcast and Replay	www.RockwellMed.com/Results
Format	Discussion of Q2FY26 results followed by Q&A

Speakers

The webcast will feature:

Mark Strobeck, Ph.D. — President and Chief Executive Officer
Jesse Neri — SVP, Chief Financial Officer

Rockwell Medical focuses on innovative growth strategies to enhance its products and processes, aiming to deliver value to the healthcare system. The company's products are vital for patients with end-stage kidney disease.